Dr. Chamindra G. Laverty, M.D.
Neurology (Neurology Physician)
200 W Arbor Dr
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Davis School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 142
Licensed in California since 2007, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of California, Davis School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A101351 (first issued 2007; current) -
Neuromuscular Medicine (Psychiatry & Neurology) Physician
CA license A101351 (first issued 2007; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 142
- Services billed
- 318
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 66 | 49 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 43 | 33 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | 11 |
| Nerve conduction, 13 or more studies | 13 | 13 |
| Nerve conduction, 9-10 studies | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Emflaza (deflazacort) | 39 |
| Pyridostigmine Bromide Other prescribers in San Diego, CA | 26 |
| Gabapentin Other prescribers in San Diego, CA | 15 |
| Evrysdi (risdiplam) | 13 |
| Azathioprine Other prescribers in San Diego, CA | 12 |
| Armodafinil | 11 |
| Skyclarys (omaveloxolone) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 42 payments worth $184,797 in total to this clinician.
| Sarepta Therapeutics, Inc. | $163,100 |
|---|---|
| Genentech USA, Inc. | $11,138 |
| Itf Therapeutics LLC | $8,189 |
| Biogen, Inc. | $2,256 |
| Genentech, Inc. | $63.92 |
| Insmed, Inc. | $33.84 |
| Novartis Pharmaceuticals Corporation | $16.84 |
| Consulting Fee | $175,717 |
|---|---|
| Education | $5,468 |
| Honoraria | $2,048 |
| Travel and Lodging | $855 |
| Food and Beverage | $710 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. Oct 8, 2025 | Consulting Fee | $13,466 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $13,134 |
| Sarepta Therapeutics, Inc. Jan 16, 2025 | Consulting Fee | $12,801 |
| Sarepta Therapeutics, Inc. Jan 16, 2025 | Consulting Fee | $12,801 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $12,469 |
| Sarepta Therapeutics, Inc. Mar 27, 2025 | Consulting Fee Elevidys · Genetic Disease | $11,815 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $10,640 |
| Sarepta Therapeutics, Inc. Jan 16, 2025 | Consulting Fee | $10,308 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $9,975 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $9,975 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Itf Therapeutics LLC Dec 22, 2025 | Consulting Fee | $5,850 |
| Itf Therapeutics LLC Dec 22, 2025 | Travel and Lodging travel to Salt Lake City, UT · in-kind | $138 |
| Itf Therapeutics LLC Dec 11, 2025 | Honoraria | $2,048 |
| Genentech USA, Inc. Nov 7, 2025 | Consulting Fee Evrysdi · Neurology | $2,900 |
| Genentech USA, Inc. Nov 5, 2025 | Consulting Fee Evrysdi · Neurology | $7,980 |
| Genentech USA, Inc. Oct 29, 2025 | Travel and Lodging Evrysdi · Neurology · travel to San Diego, CA | $108 |
| Sarepta Therapeutics, Inc. Oct 9, 2025 | Travel and Lodging travel to Vienna, Austria · in-kind | $126 |
| Sarepta Therapeutics, Inc. Oct 8, 2025 | Consulting Fee | $13,466 |
| Sarepta Therapeutics, Inc. Oct 8, 2025 | Consulting Fee | $9,975 |
| Sarepta Therapeutics, Inc. Oct 8, 2025 | Consulting Fee | $9,975 |
| Sarepta Therapeutics, Inc. Oct 8, 2025 | Consulting Fee | $831 |
| Sarepta Therapeutics, Inc. Oct 8, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Aug 25, 2025 | Education in-kind | $5,468 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $13,134 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $10,640 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $9,975 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Jul 11, 2025 | Consulting Fee | $665 |
| Biogen, Inc. Jun 5, 2025 | Consulting Fee SPINRAZA · Neurology | $2,152 |
| Sarepta Therapeutics, Inc. Apr 24, 2025 | Consulting Fee Elevidys · Genetic Disease | $3,375 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $12,469 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $9,975 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $9,975 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Apr 11, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Mar 27, 2025 | Consulting Fee Elevidys · Genetic Disease | $11,815 |
| Sarepta Therapeutics, Inc. Mar 27, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Mar 27, 2025 | Consulting Fee | $665 |
| Sarepta Therapeutics, Inc. Mar 15, 2025 | Travel and Lodging Elevidys · Genetic Disease · travel to Dallas, TX · in-kind | $483 |
| Sarepta Therapeutics, Inc. Jan 16, 2025 | Consulting Fee | $12,801 |
| Sarepta Therapeutics, Inc. Jan 16, 2025 | Consulting Fee | $12,801 |
| Sarepta Therapeutics, Inc. Jan 16, 2025 | Consulting Fee | $10,308 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $742,456 in research payments for these studies, mostly to the institutions running them.
- SRP-9003-301
Sarepta Therapeutics, Inc. - SRP-LGMD-501-NHS
Sarepta Therapeutics, Inc. - Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Itf Therapeutics LLC · Recruiting · NCT03373968 - A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Sarepta Therapeutics, Inc. · Enrolling by invitation · NCT05967351 - SRP-9005-101
Sarepta Therapeutics, Inc. - SRP-9001-401
Sarepta Therapeutics, Inc. - A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
Sarepta Therapeutics, Inc. · Active, not recruiting · NCT05881408 - A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy
Novartis Pharmaceuticals Corporation - A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Sarepta Therapeutics, Inc. · Completed · NCT05096221
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.